Journal Information
Vol. 37. Issue. 5.September - October 2017
Pages 461-562
Download PDF
More article options
Vol. 37. Issue. 5.September - October 2017
Pages 461-562
Letter to the Editor
Open Access
Switch to belatacept in kidney graft recipients
Cambio a belatacept en trasplante renal
María O. López-Olivaa,
Corresponding author

Corresponding author.
, Laura Álvareza, Mª Luisa Testillanob, Tamara Pérezb, María Fernández Nietoa, Mª José Santanaa, Elena Gonzáleza, Alicia Herrerob, Rafael Selgasa, Carlos Jiméneza
a Nephrology Department, University Hospital La Paz, Madrid, Spain
b Pharmacy Department, University Hospital La Paz, Madrid, Spain
Article information
Full Text
Download PDF
Tables (1)
Table 1. Description clinical cases.
Full Text
Dear editor:

Calcineurin inhibitors (CNIs) are the gold standard immunosuppression in kidney transplant recipients. These drugs have shown better results in graft survival and patient outcome during the first year after transplantation. However, long-term use is associated with acute and chronic nephrotoxicity, which predisposes to graft loss.

Belatacept is a fusion protein binding to CD80 or CD86 ligands on antigen presenting cells that selectively blocks T-cell costimulatory signals. Data derived from two phase III trials (BENEFIT and BENEFIT-EXT) demonstrated the efficacy and safety of Belatacept in combination with Basiliximab, steroids and mycophenolic acid preventing graft acute rejection in Epstein–Barr virus positive recipients. Recently, the results of BENEFIT and BENEFIT-EXT study after 7 year follow up confirmed former data and showed a significant reduction in death and graft loss associated with the use of belatacept.1

Given the relevance of its beneficial effects in kidney function, some authors have proposed switching CNIs into belatacept treatment in intolerant patients to calcineurin or mTOR inhibitors showing an improvement in renal function.2–5

In our country, the administration of Belatacept is restricted by public health insurance. Public hospitals may use belatacept after individualized assessment requiring specific approval by internal committees in each case.

We summarize (Table 1) our clinical experience of switching to belatacept in 5 kidney transplant recipients through 2013–2015 after failure or intolerant therapy to tacrolimus and/or everolimus. All patients were Epstein–Barr virus positive.

Table 1.

Description clinical cases.

Case 1  Case 2  Case 3  Case 4  Case 5 
Age–yr  60  49  54  44  73 
ECD/DCD/ARF  Yes/No/No  No/No/Yes  No/No/No  No/Yes/Yes  Yes/No/No 
Age - yr  60  54  52  29  60 
Sex  Male  Male  Female  Male  Male 
Induction therapy  Polyclonal ATG  Polyclonal ATG  Polyclonal ATG  Thymoglobulin  Thymoglobulin 

IS maintenance therapy 

Steroids, MMF, Tacro 1st, Cyclo 2nd 

Steroids, MMF, Tacro 

Steroids, MMF, Tacro 1st, Ever 2nd 

Steroids, MMF, Tacro 1st, Cyclo 2nd 

Steroids, MMF, Tacro 

Renal histology lesions prior to belatacept switch 


Vascular lesions, benign HTN 

Vascular lesions, CNI toxicity 

Extensive ATN 

Vascular lesions, IFTA, CNI toxicity 
Time from Tx to switch (months) 
Anti HLA antibodies
Pre-conversion  Negative  Positive (class I)  Negative  Negative  Negative 
Post-conversion  Negative  Negative  Negative  Negative  Negative 
Creatinine (mg/dl)/CKD-EPI (ml/min)
Pre-conversion  5.4/11.4  3/25.8  2.5/24.8  3.1/25.1  3.3/19 
6m post-conversion  2.29/30.7  2.1/35.2  1.5/35  1.9/47  2.7/25 
12m post-conversion  2.4/28.8  1.7/42  1.5/35.6  1.86/47  2.5/27 
Proteinuria (g/24h)
Pre-conversion  0.42  1.7  0.3  0.17  0.7 
6m post  0.7  0.7  0.2  0.14  0.45 
12m post  0.4  0.4  NA  0.07  0.29 
Acute rejection post-conversion  No  No  No  No  No 

ECD, expanded criteria donor; DCD, donor after circulatory death; ARF, Acute renal failure; IS, immunosuppression; Tx, transplantation; TMA, thrombotic microangiopathy; CNI, calcineurin inhibitors; HTN, arterial hypertension; ATN, acute tubular necrosis; IFTA, interstitial fibrosis and tubular atrophy; Tacro, Tacrolimus; Cyclo, Cyclosporine; Ever, Everolimus; MMF, mycophenolate mofetil; NA, not available.

Pre-transplant kidney biopsies were not performed. Clinical data were compatible with suboptimal donors, predisposing to a recipient poorer renal function. After transplantation patients received immunosuppression therapy consisting of anti-lymphocyte depleting antibodies, steroids and mycophenolic acid postponing tacrolimus starting to minimize delayed graft function. In four patients (cases 2, 3, 4 and 5) renal function was not adequate in the first month post-transplant. Analysis of graft biopsy showed CNI toxicity and chronic vascular lesions (likely related with donor background), but no evidence of acute rejection. Everolimus was considered an alternative to tacrolimus in all four cases. However it was not tolerated because of proteinuria or bone pain. In case 1 the reason for graft dysfunction was a thrombotic microangiopathy (TMA) due to the sequential use of tacrolimus first and cyclosporine later. They were converted to belatacept between 2 and 8 months post-transplantation showing immediate improvement of kidney function. Furthermore, anti HLA antibodies were negative after one year post-conversion.

Patients with low immunological risk (cases 1, 3, 4 and 5) received belatacept at a less intense dosage5 and in case 2 the dosage of belatacept was more intense5 due to positive class I anti-HLA antibodies (no donor specific antibodies).

All together, switching to belatacept is effective and safe in patients with failure therapy and/or intolerant to calcineurin or mTOR inhibitors at distinct time periods since transplantation. Moreover, belatacept was associated with better kidney function with no adverse events at short term and is an excellent alternative in grafts with renal dysfunction due to chronic vascular lesions or to CNI-TMA. This positive experience requires long-term assessments to confirm improvement in graft outcome.

Conflict of interest

The authors declare that they have no conflicts of interest.

F. Vincenti, L. Rostaing, J. Grinyo, K. Rice, S. Steinberg, L. Gaite, et al.
Belatacept and long-term outcomes in kidney transplantation.
N Engl J Med, 374 (2016), pp. 333-343
M. Paz, J. Roberti, F. Mos, F. Cicora.
Conversion to belatacept-based immunosuppression therapy in renal transplant patients.
Transplant Proc, 46 (2014), pp. 2987-2990
G. Gupta, A. Regmi, D. Kumar, S. Posner, M.P. Posner, A. Sharma, et al.
Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction.
Am J Transpl, 15 (2015), pp. 2726-2731
Y. Le Meur, F. Aulagnon, D. Bertrand, A.E. Heng, S. Lavaud, S. Caillard, et al.
Effect of an early switch to belatacept among CNI-intolerant graft recipients of kidneys from extended criteria donors.
Am J Transpl, 16 (2016), pp. 2181-2186
L. Rostaing, P. Massari, V.D. Garcia, E. Mancilla-Urrea, G. Nainan, M. Del Carmen Rial, et al.
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Clin J Am Soc Nephrol, 6 (2011), pp. 430-439
Copyright © 2016. Sociedad Española de Nefrología
Nefrología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?